Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC

Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

EMUC 2024: Optimising strategies in mHSPC and mCRPC

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Enzalutamide treatment boosted by Radium-223 in mCRPC

ESMO 2024: Optimising the personalisation of prostate cancer treatment

ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC

Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy